180 related articles for article (PubMed ID: 33215763)
1. Standardized Supportive Care Documentation Improves Safety of High-Dose Methotrexate Treatment.
Alsdorf WH; Karagiannis P; Langebrake C; Bokemeyer C; Frenzel C
Oncologist; 2021 Feb; 26(2):e327-e332. PubMed ID: 33215763
[TBL] [Abstract][Full Text] [Related]
2. Assessing the impact of adding acetazolamide to oral or intravenous sodium bicarbonate as compared with intravenous bicarbonate monotherapy as urinary alkalinization in adults receiving high-dose methotrexate.
Clemmons AB; Chase A; Duong P; Waller JL; Saunders K; Bryan L
Support Care Cancer; 2021 Mar; 29(3):1527-1534. PubMed ID: 32725375
[TBL] [Abstract][Full Text] [Related]
3. Letting Kids Be Kids: A Quality Improvement Project to Deliver Supportive Care at Home After High-Dose Methotrexate in Pediatric Patients With Acute Lymphoblastic Leukemia [Formula: see text].
Ranney L; Hooke MC; Robbins K
J Pediatr Oncol Nurs; 2020; 37(3):212-220. PubMed ID: 32102635
[TBL] [Abstract][Full Text] [Related]
4. Patient characteristics associated with high-risk methotrexate concentrations and toxicity.
Relling MV; Fairclough D; Ayers D; Crom WR; Rodman JH; Pui CH; Evans WE
J Clin Oncol; 1994 Aug; 12(8):1667-72. PubMed ID: 8040679
[TBL] [Abstract][Full Text] [Related]
5. Ambulatory high-dose methotrexate administration as central nervous system prophylaxis in patients with aggressive lymphoma.
Bernard S; Hachon L; Diasonama JF; Madaoui C; Aguinaga L; Miekoutima E; Moatti H; Perrial E; Madelaine I; Brice P; Thieblemont C
Ann Hematol; 2021 Apr; 100(4):979-986. PubMed ID: 33608849
[TBL] [Abstract][Full Text] [Related]
6. Monitoring Of High-Dose Methotrexate (Mtx)-Related Toxicity and Mtx Levels in Children with Acute Lymphoblastic Leukemia: A Pilot-Study in Indonesia.
Sari NM; Rakhmilla LE; Bashari MH; Zazuli Z; Suryawan N; Susanah S; Reniarti L; Raspati H; Supriyadi E; Kaspers GJL; Idjradinata P
Asian Pac J Cancer Prev; 2021 Jul; 22(7):2025-2031. PubMed ID: 34319023
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia and lymphoma.
Nakano T; Kobayashi R; Matsushima S; Hori D; Yanagi M; Suzuki D; Kobayashi K
Int J Hematol; 2021 May; 113(5):744-750. PubMed ID: 33389654
[TBL] [Abstract][Full Text] [Related]
8. Solitary serum methotrexate level 36 hours post high-dose methotrexate: A safe, efficacious, and cost-effective strategy to monitor methotrexate toxicities in childhood leukemia in resource-limited centers.
Khera S; Kapoor R; Pramanik SK
Pediatr Blood Cancer; 2020 Jul; 67(7):e28387. PubMed ID: 32400952
[TBL] [Abstract][Full Text] [Related]
9. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy.
Bacci G; Ferrari S; Longhi A; Forni C; Loro L; Beghelli C; Tremosini M; Versari M
Oncol Rep; 2003; 10(4):851-7. PubMed ID: 12792734
[TBL] [Abstract][Full Text] [Related]
10. Adverse effects with intravenous methotrexate in children with acute lymphoblastic leukemia/lymphoma: a retrospective study.
Mandal P; Samaddar S; Chandra J; Parakh N; Goel M
Indian J Hematol Blood Transfus; 2020 Jul; 36(3):498-504. PubMed ID: 32647424
[TBL] [Abstract][Full Text] [Related]
11. High-Dose Methotrexate in Pediatric Acute Lymphoblastic Leukemia: Predictors of Delayed Clearance and the Effect of Increased Hydration Rate on Methotrexate Clearance.
Chen AR; Wang YM; Lin M; Kuo DJ
Cureus; 2020 Jun; 12(6):e8674. PubMed ID: 32699674
[TBL] [Abstract][Full Text] [Related]
12. Outcomes Associated with Reducing the Urine Alkalinization Threshold in Patients Receiving High-Dose Methotrexate.
Drost SA; Wentzell JR; Giguère P; McLurg DL; Sabloff M; Kanji S; Nguyen TT
Pharmacotherapy; 2017 Jun; 37(6):684-691. PubMed ID: 28394433
[TBL] [Abstract][Full Text] [Related]
13. Plasma creatinine as predictor of delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia: A Danish population-based study.
Schmidt D; Kristensen K; Schroeder H; Wehner PS; Rosthøj S; Heldrup J; Damsgaard L; Schmiegelow K; Mikkelsen TS
Pediatr Blood Cancer; 2019 Jun; 66(6):e27637. PubMed ID: 30835935
[TBL] [Abstract][Full Text] [Related]
14. Impact of pre-hydration duration on high-dose methotrexate induced nephrotoxicity in childhood acute lymphoblastic leukaemia in resource constraint centers: a randomized crossover study.
Khera S; Mahajan D; Barbind K; Dhingra S
Cancer Chemother Pharmacol; 2023 Apr; 91(4):331-336. PubMed ID: 36951972
[TBL] [Abstract][Full Text] [Related]
15. Reduced dose folinic acid rescue after rapid high-dose methotrexate clearance is not associated with increased toxicity in a pediatric cohort.
Niinimäki R; Aarnivala H; Banerjee J; Pokka T; Vepsäläinen K; Harila-Saari A
Support Care Cancer; 2022 Jan; 30(1):127-133. PubMed ID: 34235555
[TBL] [Abstract][Full Text] [Related]
16. Assessment of renal function during high-dose methotrexate treatment in children with acute lymphoblastic leukemia.
Ylinen E; Jahnukainen K; Saarinen-Pihkala UM; Jahnukainen T
Pediatr Blood Cancer; 2014 Dec; 61(12):2199-202. PubMed ID: 25174822
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy, side effects and blood concentration monitoring of high-dose methotrexate in treatment of 180 children with acute lymphoblastic leukemia].
Wang H; Chi ZF; Li S; Wang XL; Hao LC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):949-52. PubMed ID: 21867621
[TBL] [Abstract][Full Text] [Related]
18. Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy.
Schwartz S; Borner K; Müller K; Martus P; Fischer L; Korfel A; Auton T; Thiel E
Oncologist; 2007 Nov; 12(11):1299-308. PubMed ID: 18055849
[TBL] [Abstract][Full Text] [Related]
19. Risk Factors for Delayed Elimination of Methotrexate in Children, Adolescents and Young Adults With Osteosarcoma.
Misaka KO; Suga Y; Staub Y; Tsubata A; Shimada T; Sai Y; Matsushita R
In Vivo; 2020; 34(6):3459-3465. PubMed ID: 33144454
[TBL] [Abstract][Full Text] [Related]
20. Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia.
Svahn T; Mellgren K; Harila-Saari A; Åsberg A; Kanerva J; Jónsson Ó; Vaitkeviciene G; Stamm Mikkelssen T; Schmiegelow K; Heldrup J
Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 27966809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]